Broad applicability of the Goldspire™ platform for the treatment of solid tumors.
Publication/Presentation Date
11-1-2024
Abstract
Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5-6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (NCT02507583). A Phase 2b study (NCT04485949) recently completed enrollment. Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells.
Volume
268
First Page
110373
Last Page
110373
ISSN
1521-7035
Published In/Presented At
Zilberberg, J., Uhl, C., Scott, C. B., Andrews, D. W., & Exley, M. A. (2024). Broad applicability of the Goldspire™ platform for the treatment of solid tumors. Clinical immunology (Orlando, Fla.), 268, 110373. https://doi.org/10.1016/j.clim.2024.110373
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
39349152
Department(s)
Administration and Leadership
Document Type
Article